Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MiReven Receives Further $500K from MRCF

Published: Saturday, September 15, 2012
Last Updated: Saturday, September 15, 2012
Bookmark and Share
Two high profile R&D collaborations including one with Silence Therapeutics.

MiReven has announced that it had received a further AU$500K investment from the Medical Research Commercialization Fund (MRCF) due to the successful completion of various technical and commercial milestones.

This brings the total that the MRCF has invested in MiReven since its foundation in 2010 to AU$1.1M.

MiReven has recently signed two international R&D collaborations to investigate the therapeutic efficacy of systemically delivered miR-7 in several different cancer models, thereby strengthening the potential of miR-7 as a treatment for cancer.

The first agreement is with Silence Therapeutics, announced on August 22, to use Silence’s proprietary AtuPLEX™ and DACC delivery systems to evaluate miR-7 in various cancer models. Silence will formulate a miR-7 mimetic and then use it to undertake in vitro and in vivo studies.

An important second deal, signed with another undisclosed international company, takes a similarly strategic approach to positioning miR-7 as a cancer therapeutic.

Dr Stephen Thompson, Chairman of MiReven Pty Ltd, said: “We are thrilled with our progress at MiReven. This pivotal funding from the MRCF allows MiReven to expand and undertake in vivo studies to examine the delivery of miR-7 with independent parties. The deal with Silence Therapeutics is particularly important to us as it is critically important to the development of microRNA drugs to find the right delivery method so that they can reach important cancer targets. Looking to the future, once these studies are complete, we aim to identify a development partner to take miR-7 into the clinic.”

Dr Chris Nave, Principal Executive of the MRCF commented: “MRCF is delighted to be once again backing the world class discoveries from WAIMR. In particular we would also like to thank the Western Australian government for its ongoing support of the MRCF.”

Professor Peter Klinken, Director of the WAIMR, added: "Congratulations to Peter Leedman and his WAIMR team for their exciting achievements, which have been made possible by the vision and invaluable support of the State, UWA and MRCF. The investment from all stakeholders is not only helping to commercialize WA created innovation, but also supporting high tech jobs and some of our brightest young medical researchers."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!